NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional)

The summary for the NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional): The purpose of the NHLBI SBIR Phase IIB Bridge Award is to facilitate and accelerate the capital-intensive steps that are required to transition SBIR/STTR Phase II projects to the commercialization stage by promoting partnerships between SBIR/STTR Phase II awardees and third-party investors and/or strategic partners. Applicants must submit a Commercialization Plan, which should include details on any independent third-party funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NHLBI funds being requested throughout the Phase IIB Bridge Award project period. Projects proposed in response to this FOA must relate to the NHLBI mission and require eventual Federal regulatory approval/clearance. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate, but are not required.

Federal Grant Title:	NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HL-19-017
Type of Funding:	Grant
CFDA Numbers:	93.233, 93.837, 93.838, 93.839, 93.840
CFDA Descriptions:	Information not provided
Current Application Deadline:	July 9th, 2020
Original Application Deadline:	July 9th, 2020
Posted Date:	May 16th, 2018
Creation Date:	May 16th, 2018
Archive Date:	August 14th, 2020
Total Program Funding:	$5,000,000
Maximum Federal Grant Award:	$1,000,000
Minimum Federal Grant Award:
Expected Number of Awards:	5
Cost Sharing or Matching:	No
Last Updated:	May 16th, 2018

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-19-017.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...; • NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional); • NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional); • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Cell and Gene Therapies for HIV Cure: Developing a Pipeline (P01 Clinical Trial Not Allowe...; • Ancillary Studies in Clinical Trials (R01); • Opportunity PA-08-021; • Research Demonstration and Dissemination Grants (R18)
More Grants from the National Institutes of Health: • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed); • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional); • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed); • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...